Myungmoon Pharm

At a glance

Myungmoon Pharm filed 60 disclosures in the last 12 months, including 42 insider, 3 5% holder and 1 buyback. The most recent key filing was on Oct 27: Director bought 3,351 sh on the market, Oct 26–27.

Revenue for 2025 was ₩195B, up 4.7% on 2024. Operating margin was 3.5% against 1% a year earlier. Debt was 161% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩99.2B and operating loss of ₩542.8M.

The 2025 annual report lists 309 employees with an average tenure of 9.4 years and average pay of ₩63.1M, #839 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩334.6M each on average. It paid no cash dividend for 2025. 우석민 and related parties held 21.56% at year end.

From the 2025 annual report

Staff: 309 (172 men, 137 women), of whom 12 on fixed-term contracts. Total pay for the year: ₩19.5B. Directors and auditors: 4, paid ₩1.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

우석민 holds 19.06%; with 3 related parties the group holds 21.56% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary